Lung Cancer


Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (01-17-2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients (01-15-2018)

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (01-8-2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer (01-8-2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (01-5-2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer (12-6-2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy... Continue Reading

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer (10-17-2017)

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC).  The novel immunotherapy checkpoint inhibitors Keytruda® (pembrolizumab) and Opdivo (nivolumab) are already standard of care for advanced NSCLC.1   A... Continue Reading

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer (03-11-2015)

The Food and Drug Administration has expanded approval of the PD-1 inhibitor Opdivo® (nivolumab) to include treatment of patients who have metastatic squamous non–small cell lung cancer (NSCLC) that progresses following treatment with platinum-based... Continue Reading

Study Using Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients with Targeted Therapies Transforms Care (05-22-2014)

Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has... Continue Reading

Fitness in Middle Age Reduces Cancer Risk in Men (06-21-2013)

In a large, long-term study, men with good cardiovascular fitness in middle age were less likely to develop and die from colorectal and lung cancers. These results were presented at 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Regular... Continue Reading

« Previous PageNext Page »